Professional Summary
Education & Certifications
- Fellowship: University of Texas at San Antonio (1983) TX
- Medical Education: Tulane University School of Medicine Registrar (1977) LA
- Board Certification: American Board of Internal Medicine, Medical Oncology (1983)
- Board Certification: American Board of Internal Medicine, Internal Medicine (1980)
- Residency: St Louis University Hospital (1980) MO
Honors & Awards
- APEX Award for Publication Excellence in the category of "Regular Departments & Columns", Oncology Times (2012)
- Ballve-Lantero Chair (Endowed Chair), Ballve-Lantero (1996)
- Chair, Breast Committee, Eastern Cooperative Oncology Group (ECOG) (2002-2010)
- Editor-In-Chief, Clinical Breast Cancer (1999-present)
- Gianni Bonnadona Award for Breast Cancer Research, American Society of Clinical Oncology (2020)
- Health Care Hero award, Indianapolis Business Journal (2011)
- HOPE Funds for Cancer Research 2013 Award of Excellence for Medicine, HOPE Funds, Cancer Research (April 28, 2013)
- Jill Rose Award, Breast Cancer Foundation (2007)
- Komen Brinker Award for Scientific Distinction, Susan G. Komen Breast Cancer Foundation (2006)
- Listed in "America's Top Doctors", Castle Connolly (2001-2012)
- President, American Society of Clinical Oncology, American Society of Clinical Oncology (ASCO) (2010-2011)
- William L. McGuire Award, San Antonio Breast Cancer Symposium (2010)
Administrative Appointments
- Chief, Division of Oncology, Department of Medicine (2013 - 2020)
- Professor, Medicine (2013 - Present)
Publications
-
ASCO's approach to a learning health care system in oncology.
Sledge, G. W., Hudis, C. A., Swain, S. M., Yu, P. M., Mann, J. T., Hauser, R. S., & Lichter, A. S. (2013). ASCO's approach to a learning health care system in oncology. Journal of Oncology Practice / American Society of Clinical Oncology, 9(3), 145–48. -
Characterizing the heterogeneity of triple-negative breast cancers using microdissected normal ductal epithelium and RNA-sequencing
Radovich, M., Clare, S. E., Atale, R., Pardo, I., Hancock, B. A., Solzak, J. P., … Schneider, B. P. (2014). Characterizing the heterogeneity of triple-negative breast cancers using microdissected normal ductal epithelium and RNA-sequencing. BREAST CANCER RESEARCH AND TREATMENT, 143(1), 57–68. -
Biomarker prediction of chemotherapy-related amenorrhea in premenopausal women with breast cancer participating in E5103
Ruddy, K. J., O'Neill, A., Miller, K. D., Schneider, B. P., Baker, E., Sparano, J. A., … Partridge, A. H. (2014). Biomarker prediction of chemotherapy-related amenorrhea in premenopausal women with breast cancer participating in E5103. BREAST CANCER RESEARCH AND TREATMENT, 144(3), 591–597. -
Past, Present, and Future Challenges in Breast Cancer Treatment
Sledge, G. W., Mamounas, E. P., Hortobagyi, G. N., Burstein, H. J., Goodwin, P. J., & Wolff, A. C. (2014). Past, Present, and Future Challenges in Breast Cancer Treatment. JOURNAL OF CLINICAL ONCOLOGY, 32(19), 1979–86. -
DNA double-strand break repair genes and oxidative damage in brain metastasis of breast cancer.
Woditschka, S., Evans, L., Duchnowska, R., Reed, L. T., Palmieri, D., Qian, Y., … Steeg, P. S. (2014). DNA double-strand break repair genes and oxidative damage in brain metastasis of breast cancer. Journal of the National Cancer Institute, 106(7). -
Past, present, and future challenges in breast cancer treatment.
Sledge, G. W., Mamounas, E. P., Hortobagyi, G. N., Burstein, H. J., Goodwin, P. J., & Wolff, A. C. (2014). Past, present, and future challenges in breast cancer treatment. Journal of Clinical Oncology , 32(19), 1979–86. -
Improving the quality of cancer care in America through health information technology.
Feeley, T. W., Sledge, G. W., Levit, L., & Ganz, P. A. (2014). Improving the quality of cancer care in America through health information technology. Journal of the American Medical Informatics Association , 21(5), 772–75. -
Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100
Schneider, B. P., Li, L., Shen, F., Miller, K. D., Radovich, M., O'Neill, A., … Sledge, G. W. (2014). Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100. BRITISH JOURNAL OF CANCER, 111(6), 1241–48. -
Heterogeneity and Cancer
Allison, K. H., & Sledge, G. W. (2014). Heterogeneity and Cancer. ONCOLOGY-NEW YORK, 28(9), 772–78. -
Gene Expression Analysis Reveals Distinct Pathways of Resistance to Bevacizumab in Xenograft Models of Human ER-Positive Breast Cancer
Goekmen-Polar, Y., Goswami, C. P., Toroni, R. A., Sanders, K. L., Mehta, R., Sirimalle, U., … Sledge, G. W. (2014). Gene Expression Analysis Reveals Distinct Pathways of Resistance to Bevacizumab in Xenograft Models of Human ER-Positive Breast Cancer. JOURNAL OF CANCER, 5(8), 633–645. -
Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831
Perez, E. A., Romond, E. H., Suman, V. J., Jeong, J.-H., Sledge, G., Geyer, C. E., … Wolmark, N. (2014). Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831. JOURNAL OF CLINICAL ONCOLOGY, 32(33), 3744-? -
Decade in review-targeted therapy: successes, toxicities and challenges in solid tumours.
Neal, J. W., & Sledge, G. W. (2014). Decade in review-targeted therapy: successes, toxicities and challenges in solid tumours. Nature Reviews. Clinical Oncology, 11(11), 627–28. -
Treatment-associated musculoskeletal and vasomotor symptoms and relapse-free survival in the NCIC CTG MA.27 adjuvant breast cancer aromatase inhibitor trial.
Stearns, V., Chapman, J.-A. W., Ma, C. X., Ellis, M. J., Ingle, J. N., Pritchard, K. I., … Goss, P. E. (2015). Treatment-associated musculoskeletal and vasomotor symptoms and relapse-free survival in the NCIC CTG MA.27 adjuvant breast cancer aromatase inhibitor trial. Journal of Clinical Oncology , 33(3), 265–71. -
The future of breast cancer systemic therapy: the next 10 years.
Telli, M. L., & Sledge, G. W. (2015). The future of breast cancer systemic therapy: the next 10 years. Journal of Molecular Medicine (Berlin, Germany), 93(2), 119–25. -
Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial.
Perez, E. A., Thompson, E. A., Ballman, K. V., Anderson, S. K., Asmann, Y. W., Kalari, K. R., … Reinholz, M. M. (2015). Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial. Journal of Clinical Oncology , 33(7), 701–8. -
Anti-vascular endothelial growth factor therapy in breast cancer: game over?
Sledge, G. W. (2015). Anti-vascular endothelial growth factor therapy in breast cancer: game over? Journal of Clinical Oncology , 33(2), 133–35. -
Predicting early brain metastases based on clinicopathological factors and gene expression analysis in advanced HER2-positive breast cancer patients
Duchnowska, R., Jassem, J., Goswami, C. P., Dundar, M., Goekmen-Polar, Y., Li, L., … Badve, S. (2015). Predicting early brain metastases based on clinicopathological factors and gene expression analysis in advanced HER2-positive breast cancer patients. JOURNAL OF NEURO-ONCOLOGY, 122(1), 205–216. -
A Call for Viewpoints.
Sledge, G. W., & Disis, M. L. N. (2015). A Call for Viewpoints. JAMA Oncology, 1(4), 432-? -
Targeted Therapy for Cancer in the Genomic Era.
Afghahi, A., & Sledge, G. W. (2015). Targeted Therapy for Cancer in the Genomic Era. Cancer Journal , 21(4), 294–98. -
Treatment-Associated Musculoskeletal and Vasomotor Symptoms and Relapse-Free Survival in the NCIC CTG MA.27 Adjuvant Breast Cancer Aromatase Inhibitor Trial
Stearns, V., Chapman, J.-A. W., Ma, C. X., Ellis, M. J., Ingle, J. N., Pritchard, K. I., … Goss, P. E. (2015). Treatment-Associated Musculoskeletal and Vasomotor Symptoms and Relapse-Free Survival in the NCIC CTG MA.27 Adjuvant Breast Cancer Aromatase Inhibitor Trial. JOURNAL OF CLINICAL ONCOLOGY, 33(3), 265–U163. -
Genomic Analysis Reveals That Immune Function Genes Are Strongly Linked to Clinical Outcome in the North Central Cancer Treatment Group N9831 Adjuvant Trastuzumab Trial
Perez, E. A., Thompson, E. A., Ballman, K. V., Anderson, S. K., Asmann, Y. W., Kalari, K. R., … Reinholz, M. M. (2015). Genomic Analysis Reveals That Immune Function Genes Are Strongly Linked to Clinical Outcome in the North Central Cancer Treatment Group N9831 Adjuvant Trastuzumab Trial. JOURNAL OF CLINICAL ONCOLOGY, 33(7). -
Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831.
Perez, E. A., Romond, E. H., Suman, V. J., Jeong, J.-H., Sledge, G., Geyer, C. E., … Wolmark, N. (2014). Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. Journal of Clinical Oncology , 32(33), 3744–52. -
"Vertical" Inhibition of HER2 Yields Horizontal Gains in the Clinic.
Sledge, G. W., & Pegram, M. D. (2015). "Vertical" Inhibition of HER2 Yields Horizontal Gains in the Clinic. Clinical Cancer Research , 21(12), 2663–65. -
Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100.
Schneider, B. P., Li, L., Shen, F., Miller, K. D., Radovich, M., O'Neill, A., … Sledge, G. W. (2014). Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100. British Journal of Cancer, 111(6), 1241–48. -
Everything old is neu again: cellular senescence in HER2-positive breast cancer.
Sledge, G. W., & Pegram, M. D. (2015). Everything old is neu again: cellular senescence in HER2-positive breast cancer. Journal of the National Cancer Institute, 107(5). -
Prospective Validation of a 21-Gene Expression Assay in Breast Cancer
Sparano, J. A., Gray, R. J., Makower, D. F., Pritchard, K. I., Albain, K. S., Hayes, D. F., … Sledge, G. W. (2015). Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. NEW ENGLAND JOURNAL OF MEDICINE, 373(21), 2005–14. -
Genome-Wide Association Studies for Taxane-Induced Peripheral Neuropathy in ECOG-5103 and ECOG-1199
Schneider, B. P., Li, L., Radovich, M., Shen, F., Miller, K. D., Flockhart, D. A., … Sledge, G. W. (2015). Genome-Wide Association Studies for Taxane-Induced Peripheral Neuropathy in ECOG-5103 and ECOG-1199. CLINICAL CANCER RESEARCH, 21(22), 5082–91. -
Pilot trial of paclitaxel-trastuzumab adjuvant therapy for early stage breast cancer: a trial of the ECOG-ACRIN cancer research group (E2198)
Schneider, B. P., O'Neill, A., Shen, F., Sledge, G. W., Thor, A. D., Kahanic, S. P., … Davidson, N. E. (2015). Pilot trial of paclitaxel-trastuzumab adjuvant therapy for early stage breast cancer: a trial of the ECOG-ACRIN cancer research group (E2198). BRITISH JOURNAL OF CANCER, 113(12), 1651–57. -
Curing Metastatic Breast Cancer.
Sledge, G. W. (2016). Curing Metastatic Breast Cancer. Journal of Oncology Practice / American Society of Clinical Oncology, 12(1), 6–10. -
Integrated digital error suppression for improved detection of circulating tumor DNA
Newman, A. M., Lovejoy, A. F., Klass, D. M., Kurtz, D. M., Chabon, J. J., Scherer, F., … Alizadeh, A. A. (2016). Integrated digital error suppression for improved detection of circulating tumor DNA. NATURE BIOTECHNOLOGY, 34(5), 547–55. -
Use of Gene Expression Profiling and Chemotherapy in Early-Stage Breast Cancer: A Study of Linked Electronic Medical Records, Cancer Registry Data, and Genomic Data Across Two Health Care Systems.
Afghahi, A., Mathur, M., Thompson, C. A., Mitani, A., Rigdon, J., Desai, M., … Kurian, A. W. (2016). Use of Gene Expression Profiling and Chemotherapy in Early-Stage Breast Cancer: A Study of Linked Electronic Medical Records, Cancer Registry Data, and Genomic Data Across Two Health Care Systems. Journal of Oncology Practice / American Society of Clinical Oncology, 12(6), e697–709. -
Aberrant nocturnal cortisol and disease progression in women with breast cancer
Zeitzer, J. M., Nouriani, B., Rissling, M. B., Sledge, G. W., Kaplan, K. A., Aasly, L., … Spiegel, D. (2016). Aberrant nocturnal cortisol and disease progression in women with breast cancer. BREAST CANCER RESEARCH AND TREATMENT, 158(1), 43–50. -
Classification of large circulating tumor cells isolated with ultra-high throughput microfluidic Vortex technology
Che, J., Yu, V., Dhar, M., Renier, C., Matsumoto, M., Heirich, K., … Di Carlo, D. (2016). Classification of large circulating tumor cells isolated with ultra-high throughput microfluidic Vortex technology. ONCOTARGET, 7(11), 12748–60. -
Collective Wisdom: Lobular Carcinoma of the Breast.
Sledge, G. W., Chagpar, A., & Perou, C. (2016). Collective Wisdom: Lobular Carcinoma of the Breast. American Society of Clinical Oncology Educational Book / ASCO. American Society of Clinical Oncology. Meeting, 35, 18–21. -
Synergistic drug combinations from electronic health records and gene expression.
Low, Y. S., Daugherty, A. C., Schroeder, E. A., Chen, W., Seto, T., Weber, S., … Shah, N. H. (2016). Synergistic drug combinations from electronic health records and gene expression. Journal of the American Medical Informatics Association . -
Charcot-Marie-Tooth gene, SBF2, associated with taxane-induced peripheral neuropathy in African-Americans.
Schneider, B. P., Lai, D., Shen, F., Jiang, G., Radovich, M., Li, L., … Sledge, G. W. (2016). Charcot-Marie-Tooth gene, SBF2, associated with taxane-induced peripheral neuropathy in African-Americans. Oncotarget. -
Avoidant coping and self-efficacy mediate relationships between perceived social constraints and symptoms among long-term breast cancer survivors.
Adams, R. N., Mosher, C. E., Cohee, A. A., Stump, T. E., Monahan, P. O., Sledge, G. W., … Champion, V. L. (2016). Avoidant coping and self-efficacy mediate relationships between perceived social constraints and symptoms among long-term breast cancer survivors. Psycho-Oncology. -
Effect of Unblinding on Participants' Perceptions of Risk and Confidence in a Large Double-blind Clinical Trial of Chemotherapy for Breast Cancer
Partridge, A. H., Sepucha, K., O'Neill, A., Miller, K. D., Motley, C., Swaby, R. F., … Sledge, G. W. (2015). Effect of Unblinding on Participants' Perceptions of Risk and Confidence in a Large Double-blind Clinical Trial of Chemotherapy for Breast Cancer. JAMA ONCOLOGY, 1(3), 369–74. -
Small-molecule binding sites to explore protein-protein interactions in the cancer proteome
Xu, D., Jalal, S. I., Sledge, G. W., & Meroueh, S. O. (2016). Small-molecule binding sites to explore protein-protein interactions in the cancer proteome. MOLECULAR BIOSYSTEMS, 12(10), 3067–87. -
Postmastectomy Radiotherapy: An American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Focused Guideline Update.
Recht, A., Comen, E. A., Fine, R. E., Fleming, G. F., Hardenbergh, P. H., Ho, A. Y., … Edge, S. B. (2016). Postmastectomy Radiotherapy: An American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Focused Guideline Update. Practical Radiation Oncology, 6(6), e219–e234. -
Reply to L.B. Marks et al.
Recht, A., Comen, E. A., Fine, R. E., Fleming, G. F., Hardenbergh, P. H., Ho, A. Y., … Edge, S. B. (2017). Reply to L.B. Marks et al. Journal of Clinical Oncology , JCO2016713966-? -
Postmastectomy Radiotherapy: An American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Focused Guideline Update
Recht, A., Comen, E. A., Fine, R. E., Fleming, G. F., Hardenbergh, P. H., Ho, A. Y., … Edge, S. B. (2016). Postmastectomy Radiotherapy: An American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Focused Guideline Update. JOURNAL OF CLINICAL ONCOLOGY, 34(36). -
Research needs in breast cancer.
Cardoso, F., Harbeck, N., Barrios, C. H., Bergh, J., Cortés, J., El Saghir, N., … Gelmon, K. A. (2016). Research needs in breast cancer. Annals of Oncology . -
Genome-Wide Association Study for Anthracycline-Induced Congestive Heart Failure.
Schneider, B. P., Shen, F., Gardner, L., Radovich, M., Li, L., Miller, K. D., … Sledge, G. W. (2017). Genome-Wide Association Study for Anthracycline-Induced Congestive Heart Failure. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 23(1), 43–51. -
Postmastectomy Radiotherapy: An American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Focused Guideline Update
Recht, A., Comen, E. A., Fine, R. E., Fleming, G. F., Hardenbergh, P. H., Ho, A. Y., … Edge, S. B. (2017). Postmastectomy Radiotherapy: An American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Focused Guideline Update. ANNALS OF SURGICAL ONCOLOGY, 24(1), 38–51. -
Put Some PEPI in Your Step: Ki67's Long Road to Respectability.
Sledge, G. W. (2017). Put Some PEPI in Your Step: Ki67's Long Road to Respectability. Journal of Clinical Oncology , JCO2016712182-? -
Research needs in breast cancer
Cardoso, F., Harbeck, N., Barrios, C. H., Bergh, J., Cortes, J., El Saghir, N., … Gelmon, K. A. (2017). Research needs in breast cancer. ANNALS OF ONCOLOGY, 28(2), 208–17. -
Osteoporosis therapy and outcomes for postmenopausal patients with hormone receptor-positive breast cancer: NCIC CTG MA.27.
Lipton, A., Chapman, J.-A. W., Leitzel, K., Garg, A., Pritchard, K. I., Ingle, J. N., … Ali, S. M. (2017). Osteoporosis therapy and outcomes for postmenopausal patients with hormone receptor-positive breast cancer: NCIC CTG MA.27. Cancer. -
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy.
Sledge, G. W., Toi, M., Neven, P., Sohn, J., Inoue, K., Pivot, X., … Llombart-Cussac, A. (2017). MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. Journal of Clinical Oncology , JCO2017737585-? -
Molecular Characterization and Mortality From Breast Cancer in Men.
Massarweh, S. A., Sledge, G. W., Miller, D. P., McCullough, D., Petkov, V. I., & Shak, S. (2018). Molecular Characterization and Mortality From Breast Cancer in Men. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO2017768861. -
Higher Absolute Lymphocyte Counts Predict Lower Mortality from Early-Stage Triple-Negative Breast Cancer.
Afghahi, A., Purington, N., Han, S. S., Desai, M., Pierson, E., Mathur, M. B., … Kurian, A. W. (2018). Higher Absolute Lymphocyte Counts Predict Lower Mortality from Early-Stage Triple-Negative Breast Cancer. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. -
Circulating tumor cells (CTCs) five years after diagnosis are prognostic for late recurrence in operable stage II-III breast cancer
Sparano, J. A., O'Neill, A., Alpaugh, K., Wolff, A. C., Northfelt, D. W., Dang, C., … Miller, K. D. (2018). Circulating tumor cells (CTCs) five years after diagnosis are prognostic for late recurrence in operable stage II-III breast cancer. CANCER RESEARCH, 78(4). -
Altered expression of telomere-associated genes in leukocytes among BRCA1 and BRCA2 carriers
Tanaka, H., Phipps, E. A., Wei, T., Wu, X., Goswami, C., Liu, Y., … Herbert, B.-S. (2018). Altered expression of telomere-associated genes in leukocytes among BRCA1 and BRCA2 carriers. MOLECULAR CARCINOGENESIS, 57(4), 567–75. -
Does biomarker information impact breast cancer patients' preferences and physician recommendation for adjuvant chemotherapy?
Partridge, A. H., Sepucha, K., O'Neill, A., Miller, K. D., Baker, E., Dang, C. T., … Schneider, B. P. (2017). Does biomarker information impact breast cancer patients' preferences and physician recommendation for adjuvant chemotherapy? BREAST CANCER RESEARCH AND TREATMENT, 165(3), 545–53. -
Molecular characterization and mortality from breast cancer in men
Massarweh, S. A., Sledge, G. W., Miller, D. P., McCullough, D., Petkov, V. I., & Shak, S. (2018). Molecular characterization and mortality from breast cancer in men. CANCER RESEARCH, 78(4). -
The benefit of abemaciclib in prognostic subgroups: An exploratory analysis of combined data from the MONARCH 2 and 3 studies
Goetz, M. P., O'Shaughnessy, J., Sledge, G. W., Martin, M., Lin, Y., Forrester, T., … Johnston, S. (2018). The benefit of abemaciclib in prognostic subgroups: An exploratory analysis of combined data from the MONARCH 2 and 3 studies. CANCER RESEARCH, 78(4). -
Patient-reported predictors of early treatment discontinuation: treatment-related symptoms and health-related quality of life among postmenopausal women with primary breast cancer randomized to anastrozole or exemestane on NCIC Clinical Trials Group (CCTG) MA.27 (E1Z03)
Wagner, L. I., Zhao, F., Goss, P. E., Chapman, J.-A. W., Shepherd, L. E., Whelan, T. J., … Cella, D. (2018). Patient-reported predictors of early treatment discontinuation: treatment-related symptoms and health-related quality of life among postmenopausal women with primary breast cancer randomized to anastrozole or exemestane on NCIC Clinical Trials Group (CCTG) MA.27 (E1Z03). BREAST CANCER RESEARCH AND TREATMENT, 169(3), 537–48. -
Efficacy and safety of abemaciclib in patients with liver metastases in the MONARCH 1, 2, and 3 studies
Di Leo, A., Dickler, M., Sledge, G. W., Toi, M., Forrester, T., Nanda, S., … Johnston, S. (2018). Efficacy and safety of abemaciclib in patients with liver metastases in the MONARCH 1, 2, and 3 studies. CANCER RESEARCH, 78(4). -
Local Control of Distant Disease: Yes, but Where to Next?
Sledge, G. W. (2018). Local Control of Distant Disease: Yes, but Where to Next? Journal of Oncology Practice, 14(6), 357–58. -
Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node-Positive and High-Risk Lymph Node-Negative Breast Cancer (E5103).
Miller, K. D., O'Neill, A., Gradishar, W., Hobday, T. J., Goldstein, L. J., Mayer, I. A., … Sledge, G. W. (2018). Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node-Positive and High-Risk Lymph Node-Negative Breast Cancer (E5103). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO2018792028. -
Lymphopenia after adjuvant radiotherapy (RT) to predict poor survival in triple-negative breast cancer (TNBC).
Afghahi, A., Mathur, M., Seto, T., Desai, M., Kenkare, P., Horst, K. C., … Sledge, G. W. (2015). Lymphopenia after adjuvant radiotherapy (RT) to predict poor survival in triple-negative breast cancer (TNBC). JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. -
Effects of Celecoxib and Low-dose Aspirin on Outcomes in Adjuvant Aromatase Inhibitor-Treated Patients: CCTG MA.27
Strasser-Weippl, K., Higgins, M. J., Chapman, J.-A. W., Ingle, J. N., Sledge, G. W., Budd, G. T., … Goss, P. E. (2018). Effects of Celecoxib and Low-dose Aspirin on Outcomes in Adjuvant Aromatase Inhibitor-Treated Patients: CCTG MA.27. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 110(9), 1003–8. -
Prognostic characteristics in hormone receptor-positive advanced breast cancer and characterization of abemaciclib efficacy.
Di Leo, A., O'Shaughnessy, J., Sledge, G. W., Martin, M., Lin, Y., Frenzel, M., … Johnston, S. (2018). Prognostic characteristics in hormone receptor-positive advanced breast cancer and characterization of abemaciclib efficacy. NPJ Breast Cancer, 4, 41. -
Association of Circulating Tumor Cells With Late Recurrence of Estrogen Receptor-Positive Breast Cancer A Secondary Analysis of a Randomized Clinical Trial
Sparano, J., O'Neill, A., Alpaugh, K., Wolff, A. C., Northfelt, D. W., Dang, C. T., … Miller, K. D. (2018). Association of Circulating Tumor Cells With Late Recurrence of Estrogen Receptor-Positive Breast Cancer A Secondary Analysis of a Randomized Clinical Trial. JAMA ONCOLOGY, 4(12), 1700–1706. -
Change in survival in metastatic breast cancer with treatment advances: meta-analysis and systematic review
Caswell-Jin, J. L., Plevritis, S. K., Tian, L., Cadham, C. J., Xu, C., Stout, N. K., … Kurian, A. W. (2018). Change in survival in metastatic breast cancer with treatment advances: meta-analysis and systematic review. JNCI Cancer Spectrum, 2(4). -
Patients and Physicians in the Era of Modern Cancer Care.
Sledge, G. W. (2019). Patients and Physicians in the Era of Modern Cancer Care. JAMA. -
Targeting CXCR4-induced desmoplasia to improve checkpoint inhibition in breast cancer.
Sledge, G. W. (2019). Targeting CXCR4-induced desmoplasia to improve checkpoint inhibition in breast cancer. Proceedings of the National Academy of Sciences of the United States of America. -
Collective Wisdom: Lobular Carcinoma of the Breast.
Sledge, G. W., Chagpar, A., & Perou, C. (2016). Collective Wisdom: Lobular Carcinoma of the Breast. American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting, (36), 18–21. -
Urgent hypertension as a biomarker for bevacizumab in the curative setting.
Kassem, N., Shen, F., Jiang, G., Gardner, L., Philips, S., O'Neill, A. M., … Schneider, B. P. (2018). Urgent hypertension as a biomarker for bevacizumab in the curative setting. JOURNAL OF CLINICAL ONCOLOGY, 36(15). -
TAILORx: Phase III trial of chemoendocrine therapy versus endocrine therapy alone in hormone receptor-positive, HER2-negative, node-negative breast cancer and an intermediate prognosis 21-gene recurrence score.
Sparano, J. A., Gray, R. J., Wood, W. C., Makower, D. F., Lively, T. G., Saphner, T. J., … Sledge, G. W. (2018). TAILORx: Phase III trial of chemoendocrine therapy versus endocrine therapy alone in hormone receptor-positive, HER2-negative, node-negative breast cancer and an intermediate prognosis 21-gene recurrence score. JOURNAL OF CLINICAL ONCOLOGY, 36(18). -
Impact of Genetic Ancestry on Outcomes in ECOG-ACRIN-E5103.
Schneider, B. P., Shen, F., Jiang, G., O'Neill, A., Radovich, M., Li, L., … Miller, K. D. (2017). Impact of Genetic Ancestry on Outcomes in ECOG-ACRIN-E5103. JCO Precision Oncology, 2017. -
PRECISION/PERSONALIZED MEDICINE: HOPES AND HYPES
Sledge, G. W. (2017). PRECISION/PERSONALIZED MEDICINE: HOPES AND HYPES. BREAST, 36, S26. -
MONARCH 2: Abemaciclib in combination with fulvestrant in patients with HR+/HER2-advanced breast cancer who progressed on endocrine therapy
Sledge, G. W., Toi, M., Neven, P., Sohn, J., Inoue, K., Pivot, X. B., … Llombart-Cussac, A. (2017). MONARCH 2: Abemaciclib in combination with fulvestrant in patients with HR+/HER2-advanced breast cancer who progressed on endocrine therapy. JOURNAL OF CLINICAL ONCOLOGY, 35. -
A Phase I/II study of suberoylanilide hydroxamic acid (SAHA) in combination with trastuzumab (Herceptin) in patients with advanced metastatic and/or local chest wall recurrent HER2-amplified breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1104)
Goldstein, L. J., Zhao, F., Wang, M., Swaby, R. F., Sparano, J. A., Meropol, N. J., … Sledge, G. W. (2017). A Phase I/II study of suberoylanilide hydroxamic acid (SAHA) in combination with trastuzumab (Herceptin) in patients with advanced metastatic and/or local chest wall recurrent HER2-amplified breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1104). BREAST CANCER RESEARCH AND TREATMENT, 165(2), 375–82. -
Survival Benefit Needed to Undergo Chemotherapy: Patient and Physician Preferences
Vaz-Luis, I., O'Neill, A., Sepucha, K., Miller, K. D., Baker, E., Dang, C. T., … Partridge, A. H. (2017). Survival Benefit Needed to Undergo Chemotherapy: Patient and Physician Preferences. CANCER, 123(15), 2821–28. -
Quality of life difficulties in partners of young breast cancer survivors.
Champion, V., Cohee, A. A., Monahan, P., Stump, T. E., Miller, K., Wagner, L., … Sledge, G. (2016). Quality of life difficulties in partners of young breast cancer survivors. JOURNAL OF CLINICAL ONCOLOGY, 34(3). -
Adjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Detour on the Road to a Cure
Sledge, G. W. (2016). Adjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Detour on the Road to a Cure. JOURNAL OF CLINICAL ONCOLOGY, 34(10), 1021-+. -
IS A TWO-SPEED (RICH VS POOR) ONCOLOGY INEVITABLE?
Sledge, G. W. (2015). IS A TWO-SPEED (RICH VS POOR) ONCOLOGY INEVITABLE? BREAST, 24, S34. -
Bevacizumab (Bv) in the adjuvant treatment of HER2-negative breast cancer: Final results from Eastern Cooperative Oncology Group E5103
Miller, K., O'Neill, A. M., Dang, C. T., Northfelt, D. W., Gradishar, W. J., Goldstein, L. J., … Sledge, G. W. (2014). Bevacizumab (Bv) in the adjuvant treatment of HER2-negative breast cancer: Final results from Eastern Cooperative Oncology Group E5103. JOURNAL OF CLINICAL ONCOLOGY, 32(15). -
A phase III randomized trial of niraparib versus physician's choice in previously treated, HER2-negative, germline-BRCA mutated breast cancer patients: Intergroup study EORTC4307-BCG and BIG5-13
Tryfonidis, K., Bogaerts, J., Martell, R. E., Sledge, G. W., Balmana, J., Audeh, M. W., … Turner, N. C. (2014). A phase III randomized trial of niraparib versus physician's choice in previously treated, HER2-negative, germline-BRCA mutated breast cancer patients: Intergroup study EORTC4307-BCG and BIG5-13. JOURNAL OF CLINICAL ONCOLOGY, 32(15). -
Recurrence score and clinicopathologic characteristics of TAILORx participants by race and ethnicity.
Rubinstein, M. M. Z., Gray, R. J., Sparano, J. A., Zujewski, J. A., Whelan, T. J., Albain, K. S., … Sledge, G. W. (2015). Recurrence score and clinicopathologic characteristics of TAILORx participants by race and ethnicity. JOURNAL OF CLINICAL ONCOLOGY, 33(15). -
Recurrence score and clinicopathologic characteristics of TAILORx participants by race and ethnicity
Sparano, J. A., Gray, R. J., Zujewski, J. A., Whelan, T. J., Albain, K. S., Hayes, D., … Sledge, G. W. (2014). Recurrence score and clinicopathologic characteristics of TAILORx participants by race and ethnicity. JOURNAL OF CLINICAL ONCOLOGY, 32(26). -
A phase III study of abemaciclib (LY2835219) combined with fulvestrant in women with hormone receptor positive (HR plus ), human epidermal growth factor receptor 2 negative (HER2-) breast cancer (MONARCH 2)
Llombart, A., Toi, M., Klise, S. R., Frenzel, M., Chan, E. M., & Sledge, G. W. (2015). A phase III study of abemaciclib (LY2835219) combined with fulvestrant in women with hormone receptor positive (HR plus ), human epidermal growth factor receptor 2 negative (HER2-) breast cancer (MONARCH 2). CANCER RESEARCH, 75. -
Ten year update of E1199: Phase III study of doxorubicin-cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in patients with axillary node-positive or high-risk node-negative breast cancer
Sparano, J. A., Zhao, F., Martino, S., Ligibel, J., Saphner, T., Wolff, A. C., … Davidson, N. E. (2015). Ten year update of E1199: Phase III study of doxorubicin-cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in patients with axillary node-positive or high-risk node-negative breast cancer. CANCER RESEARCH, 75. -
Delivering high-quality cancer care: The critical role of quality measurement
Spinks, T. E., Ganz, P. A., Sledge, G. W., Levit, L., Hayman, J. A., Eberlein, T. J., & Feeley, T. W. (2014). Delivering high-quality cancer care: The critical role of quality measurement. HEALTHCARE-THE JOURNAL OF DELIVERY SCIENCE AND INNOVATION, 2(1), 53–62. -
Association of genomic analysis of immune function genes and clinical outcome in the NCCTG (Alliance) N9831 adjuvant trastuzumab trial.
Perez, E. A., Thompson, E. A., Anderson, S. K., Asmann, Y. W., Kalari, K. R., Eckel-Passow, J., … Ballman, K. V. (2014). Association of genomic analysis of immune function genes and clinical outcome in the NCCTG (Alliance) N9831 adjuvant trastuzumab trial. JOURNAL OF CLINICAL ONCOLOGY, 32(15). -
Biomarker prediction of chemotherapy-related amenorrhea.
Ruddy, K. J., O'Neill, A. M., Miller, K., Schneider, B. P., Baker, E., Sparano, J. A., … Sledge, G. W. (2013). Biomarker prediction of chemotherapy-related amenorrhea. JOURNAL OF CLINICAL ONCOLOGY, 31(15). -
Does biomarker information impact patients' preferences for therapy?
Partridge, A. H., Sepucha, K., O'Neill, A., Miller, K., Baker, E., Dang, C. T., … Schneider, B. P. (2013). Does biomarker information impact patients' preferences for therapy? JOURNAL OF CLINICAL ONCOLOGY, 31(15). -
Lessons learned from the development of the CancerLinQ prototype: Clinical decision support.
Schilsky, R. L., Swain, S. M., Hauser, R., Mann, J., Sledge, G. W., Yu, P. P., … Hudis, C. (2013). Lessons learned from the development of the CancerLinQ prototype: Clinical decision support. JOURNAL OF CLINICAL ONCOLOGY, 31(31). -
TCGA's Breast Cancer Project May Yield Important Therapeutic Benefits, but It's Too Early to Be Sure
Radovich, M., & Sledge, G. W. (2013). TCGA's Breast Cancer Project May Yield Important Therapeutic Benefits, but It's Too Early to Be Sure. ONCOLOGY-NEW YORK, 27(12), 1280-+. -
ADVANCES IN ADVANCED TRIPLE NEGATIVE BREAST CANCER
Sledge, G. W. (2013). ADVANCES IN ADVANCED TRIPLE NEGATIVE BREAST CANCER. BREAST, 22, S19. -
Tumor Molecular Profiling Aids in Determining Tissue of Origin and Therapy for Metastatic Adenocarcinoma in a Patient With Multiple Primary Malignancies
Costa, H. A., Reyes, R., Mills, M., Zehnder, J. L., Sledge, G., Curtis, C., … Suarez, C. J. (2018). Tumor Molecular Profiling Aids in Determining Tissue of Origin and Therapy for Metastatic Adenocarcinoma in a Patient With Multiple Primary Malignancies. JCO PRECISION ONCOLOGY, 2. -
Change in Survival in Metastatic Breast Cancer with Treatment Advances: Meta-Analysis and Systematic Review.
Caswell-Jin, J. L., Plevritis, S. K., Tian, L., Cadham, C. J., Xu, C., Stout, N. K., … Kurian, A. W. (2018). Change in Survival in Metastatic Breast Cancer with Treatment Advances: Meta-Analysis and Systematic Review. JNCI Cancer Spectrum, 2(4), pky062. -
Real-Time Detection of Circulating Tumor Cells in Living Animals Using Functionalized Large Gold Nanorods.
Dutta, R., Liba, O., SoRelle, E. D., Winetraub, Y., Ramani, V. C., Jeffrey, S. S., … de la Zerda, A. (2019). Real-Time Detection of Circulating Tumor Cells in Living Animals Using Functionalized Large Gold Nanorods. Nano Letters, 19(4), 2334–42. -
Pilot trial of paclitaxel-trastuzumab adjuvant therapy for early stage breast cancer: a trial of the ECOG-ACRIN cancer research group (E2198).
Schneider, B. P., O'Neill, A., Shen, F., Sledge, G. W., Thor, A. D., Kahanic, S. P., … Davidson, N. E. (2015). Pilot trial of paclitaxel-trastuzumab adjuvant therapy for early stage breast cancer: a trial of the ECOG-ACRIN cancer research group (E2198). British Journal of Cancer, 113(12), 1651–7. -
Targeting CXCR4-induced desmoplasia to improve checkpoint inhibition in breast cancer
Sledge, G. W. (2019). Targeting CXCR4-induced desmoplasia to improve checkpoint inhibition in breast cancer. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 116(11), 4769–71. -
Personalized Decision Making in Early Stage Breast Cancer: Applying Clinical Prediction Models for Anthracycline Cardiotoxicity and Breast Cancer Mortality Demonstrates Substantial Heterogeneity of Benefit-Harm Trade-off.
Upshaw, J. N., Ruthazer, R., Miller, K. D., Parsons, S. K., Erban, J. K., O'Neill, A. M., … Kent, D. M. (2019). Personalized Decision Making in Early Stage Breast Cancer: Applying Clinical Prediction Models for Anthracycline Cardiotoxicity and Breast Cancer Mortality Demonstrates Substantial Heterogeneity of Benefit-Harm Trade-off. Clinical Breast Cancer. -
The benefit of abemaciclib in prognostic subgroups: An update to the pooled analysis of MONARCH 2 and 3
O'Shaughnessy, J., Goetz, M. P., Sledge, G. W., Martin, M., Lin, Y., Forrester, T., … Johnston, S. (2018). The benefit of abemaciclib in prognostic subgroups: An update to the pooled analysis of MONARCH 2 and 3. CANCER RESEARCH, 78(13). -
Higher Absolute Lymphocyte Counts Predict Lower Mortality from Early-Stage Triple-Negative Breast Cancer
Afghahi, A., Purington, N., Han, S. S., Desai, M., Pierson, E., Mathur, M. B., … Kurian, A. W. (2018). Higher Absolute Lymphocyte Counts Predict Lower Mortality from Early-Stage Triple-Negative Breast Cancer. CLINICAL CANCER RESEARCH, 24(12), 2851–58. -
Integrated digital error suppression for noninvasive detection of circulating tumor DNA in NSCLC.
Newman, A. M., Lovejoy, A. F., Klass, D. M., Kurtz, D. M., Chabon, J. J., Scherer, F., … Diehn, M. (2016). Integrated digital error suppression for noninvasive detection of circulating tumor DNA in NSCLC. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. -
Higher peripheral lymphocyte count to predict survival in triple-negative breast cancer (TNBC).
Afghahi, A., Rigdon, J., Purington, N., Desal, M., Pierson, E., Mathur, M., … Kurian, A. W. (2016). Higher peripheral lymphocyte count to predict survival in triple-negative breast cancer (TNBC). JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. -
Investigating circulating tumor cells and distant metastases in patient-derived orthotopic xenograft models of triple-negative breast cancer.
Ramani, V. C., Lemaire, C. A., Triboulet, M., Casey, K. M., Heirich, K., Renier, C., … Jeffrey, S. S. (2019). Investigating circulating tumor cells and distant metastases in patient-derived orthotopic xenograft models of triple-negative breast cancer. Breast Cancer Research : BCR, 21(1), 98. -
Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical Trial.
Sparano, J. A., Gray, R. J., Makower, D. F., Albain, K. S., Saphner, T. J., Badve, S. S., … Sledge, G. W. (2019). Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical Trial. JAMA Oncology. -
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial.
Sledge, G. W., Toi, M., Neven, P., Sohn, J., Inoue, K., Pivot, X., … Llombart-Cussac, A. (2019). The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial. JAMA Oncology. -
Radiomics features to identify distinct subtypes of triple-negative breast cancers.
Itakura, H., Ikeda, D. M., Okamoto, S., Chen, S.-T., Rister, B., Gude, D., … Kurian, A. W. (2019). Radiomics features to identify distinct subtypes of triple-negative breast cancers. JOURNAL OF CLINICAL ONCOLOGY, 37(15). -
Impact of clinical risk category on prognosis and prediction of chemotherapy benefit in early breast cancer (EBC) by age and the 21-gene recurrence score (RS) in TAILORx.
Sparano, J. A., Gray, R. J., Makower, D. F., Lively, T. G., Saphner, T. J., Keane, M. M., … Sledge, G. W. (2019). Impact of clinical risk category on prognosis and prediction of chemotherapy benefit in early breast cancer (EBC) by age and the 21-gene recurrence score (RS) in TAILORx. JOURNAL OF CLINICAL ONCOLOGY, 37(15). -
Gold Nanobipyramids as Second Near Infrared Optical Coherence Tomography Contrast Agents for in Vivo Multiplexing Studies.
Si, P., Shevidi, S., Yuan, E., Yuan, K., Lautman, Z., Jeffrey, S. S., … de la Zerda, A. (2019). Gold Nanobipyramids as Second Near Infrared Optical Coherence Tomography Contrast Agents for in Vivo Multiplexing Studies. Nano Letters. -
Susan G. Komen Big Data for Breast Cancer Initiative: How Patient Advocacy Organizations Can Facilitate Using Big Data to Improve Patient Outcomes
Jourquin, J., Reffey, S. B., Jernigan, C., Levy, M., Zinser, G., Sabelko, K., … Sledge, G. (2019). Susan G. Komen Big Data for Breast Cancer Initiative: How Patient Advocacy Organizations Can Facilitate Using Big Data to Improve Patient Outcomes. JCO PRECISION ONCOLOGY, 3. -
Impact of Genetic Ancestry on Outcomes in ECOG-ACRIN-5103
Schneider, B. P., Shen, F., Jiang, G., O'Neill, A., Radovich, M., Li, L., … Miller, K. D. (2017). Impact of Genetic Ancestry on Outcomes in ECOG-ACRIN-5103. JCO PRECISION ONCOLOGY, 1. -
Patients and Physicians in the Era of Modern Cancer Care
Sledge, G. W. (2019). Patients and Physicians in the Era of Modern Cancer Care. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 321(9), 829–30. -
Prognostic characteristics in hormone receptor-positive advanced breast cancer and characterization of abemaciclib efficacy
Di Leo, A., O'Shaughnessy, J., Sledge, G. W., Martin, M., Lin, Y., Frenzel, M., … Johnston, S. (2018). Prognostic characteristics in hormone receptor-positive advanced breast cancer and characterization of abemaciclib efficacy. NPJ BREAST CANCER, 4. -
Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node-Positive and High-Risk Lymph Node-Negative Breast Cancer (E5103)
Miller, K. D., O'Neill, A., Gradishar, W., Hobday, T. J., Goldstein, L. J., Mayer, I. A., … Sledge, G. W. (2018). Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node-Positive and High-Risk Lymph Node-Negative Breast Cancer (E5103). JOURNAL OF CLINICAL ONCOLOGY, 36(25), 2621-+. -
Local Control of Distant Disease: Yes, but Where to Next?
Sledge, G. W. (2018). Local Control of Distant Disease: Yes, but Where to Next? JOURNAL OF ONCOLOGY PRACTICE, 14(6), 357-+. -
Phase 1, open-label, dose-escalation and expansion study of ABT-165, a dual variable domain immunoglobulin (DVD-Ig) targeting both DLL4 and VEGF, in patients (pts) with advanced solid tumors.
Gordon, M. S., Nemunaitis, J. J., Ramanathan, R. K., Sledge, G. W., Wang, L., Fan, X., … Strickler, J. H. (2016). Phase 1, open-label, dose-escalation and expansion study of ABT-165, a dual variable domain immunoglobulin (DVD-Ig) targeting both DLL4 and VEGF, in patients (pts) with advanced solid tumors. JOURNAL OF CLINICAL ONCOLOGY, 34(15). -
Association of Charcot-Marie-Tooth gene, SBF2, with taxane-induced peripheral neuropathy in African Americans.
Schneider, B. P., Lai, D., Shen, F., Jiang, G., Radovich, M., Li, L., … Sledge, G. W. (2016). Association of Charcot-Marie-Tooth gene, SBF2, with taxane-induced peripheral neuropathy in African Americans. JOURNAL OF CLINICAL ONCOLOGY, 34(15). -
Genome wide association study for anthracycline-induced congestive heart failure.
Gardner, L., Shen, F., Radovich, M., Li, L., Miller, K., Pan, G., … Schneider, B. P. (2016). Genome wide association study for anthracycline-induced congestive heart failure. JOURNAL OF CLINICAL ONCOLOGY, 34(15). -
A phase II prospective trial correlating progression-free survival (PFS) with CYP2D6 activity in patients with metastatic breast cancer treated with tamoxifen: ECOG-ACRIN E3108.
Stearns, V., O'Neill, A. M., Schneider, B. P., Flockhart, D. A., Skaar, T. C., Liu, M. C., … Sledge, G. W. (2016). A phase II prospective trial correlating progression-free survival (PFS) with CYP2D6 activity in patients with metastatic breast cancer treated with tamoxifen: ECOG-ACRIN E3108. JOURNAL OF CLINICAL ONCOLOGY, 34(15). -
Clinical significance of PIK3CA and ESR1 mutations in ctDNA and FFPE samples from the MONARCH 2 study of abemaciclib plus fulvestrant
Tolaney, S. M., Toi, M., Neven, P., Sohn, J., Grischke, E.-M., Llombart-Cussac, A., … Sledge, G. W. (2019). Clinical significance of PIK3CA and ESR1 mutations in ctDNA and FFPE samples from the MONARCH 2 study of abemaciclib plus fulvestrant. CANCER RESEARCH, 79(13). -
Health-Related Quality of Life in MONARCH 2: Abemaciclib plus Fulvestrant in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer After Endocrine Therapy.
Kaufman, P. A., Toi, M., Neven, P., Sohn, J., Grischke, E.-M., Andre, V., … Sledge, G. W. (2019). Health-Related Quality of Life in MONARCH 2: Abemaciclib plus Fulvestrant in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer After Endocrine Therapy. The Oncologist. -
THE ROLE OF BIG DATA AND REAL WORLD DATA
Sledge, G. W. (2019). THE ROLE OF BIG DATA AND REAL WORLD DATA. BREAST, 48, S22. -
Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical Considerations
Dowling, R. J. O., Kalinsky, K., Hayes, D. F., Bidard, F.-C., Cescon, D. W., Chandarlapaty, S., … Goodwin, P. J. (2019). Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical Considerations. JNCI CANCER SPECTRUM, 3(4). -
Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 2: Approaches to Predict and Identify Late Recurrence, Research Directions
Dowling, R. J. O., Sparano, J. A., Goodwin, P. J., Bidard, F.-C., Cescon, D. W., Chandarlapaty, S., … Hayes, D. F. (2019). Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 2: Approaches to Predict and Identify Late Recurrence, Research Directions. JNCI CANCER SPECTRUM, 3(4). -
Patient familiarity with, understanding of, and preferences for clinical trial endpoints and terminology.
von Itzstein, M. S., Railey, E., Smith, M. L., White, C. B., Sledge, G. W., Howell, J. R., … Gerber, D. E. (2020). Patient familiarity with, understanding of, and preferences for clinical trial endpoints and terminology. Cancer. -
Using natural language processing to construct a metastatic breast cancer cohort from linked cancer registry and electronic medical records data.
Ling, A. Y., Kurian, A. W., Caswell-Jin, J. L., Sledge, G. W., Shah, N. H., & Tamang, S. R. (2019). Using natural language processing to construct a metastatic breast cancer cohort from linked cancer registry and electronic medical records data. JAMIA Open, 2(4), 528–37. -
Health-Related Quality of Life in MONARCH 2: Abemaciclib plus Fulvestrant in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer After Endocrine Therapy.
Kaufman, P. A., Toi, M., Neven, P., Sohn, J., Grischke, E.-M. M., Andre, V., … Sledge, G. W. (2020). Health-Related Quality of Life in MONARCH 2: Abemaciclib plus Fulvestrant in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer After Endocrine Therapy. The Oncologist, 25(2), e243–e251. -
Monarch 2: Interim Overall Survival of Abemaciclib Plus Fulvestrant in Patients with HR+, HER2-Advanced Breast Cancer
Grischke, E. M., Sledge, G. W., Toi, M., Neven, P., Sohn, J. H., Inoue, K., … Llombart-Cussac, A. (2020). Monarch 2: Interim Overall Survival of Abemaciclib Plus Fulvestrant in Patients with HR+, HER2-Advanced Breast Cancer. ONCOLOGY RESEARCH AND TREATMENT, 43, 15. -
Clinical Significance of PIK3CA and ESR1 Mutations in CTDNA and FFPE Samples from The Monarch2 Study of Abemaciclib Plus Fulvestrant
Grischke, E. M., Tolaney, S., Toi, M., Neven, P., Sohn, J. H., Llombart-Cussac, A., … Sledge, G. W. (2020). Clinical Significance of PIK3CA and ESR1 Mutations in CTDNA and FFPE Samples from The Monarch2 Study of Abemaciclib Plus Fulvestrant. ONCOLOGY RESEARCH AND TREATMENT, 43, 9–10. -
Patient-Reported Cognitive Impairment Among Women With Early Breast Cancer Randomly Assigned to Endocrine Therapy Alone Versus Chemoendocrine Therapy: Results From TAILORx.
Wagner, L. I., Gray, R. J., Sparano, J. A., Whelan, T. J., Garcia, S. F., Yanez, B., … Cella, D. (2020). Patient-Reported Cognitive Impairment Among Women With Early Breast Cancer Randomly Assigned to Endocrine Therapy Alone Versus Chemoendocrine Therapy: Results From TAILORx. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO1901866. -
Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical Considerations.
Dowling, R. J., Kalinsky, K., Hayes, D. F., Bidard, F.-C. C., Cescon, D. W., Chandarlapaty, S., … Goodwin, P. J. (2019). Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical Considerations. JNCI Cancer Spectrum, 3(4), pkz050. -
Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 2: Approaches to Predict and Identify Late Recurrence, Research Directions.
Dowling, R. J., Sparano, J. A., Goodwin, P. J., Bidard, F.-C. C., Cescon, D. W., Chandarlapaty, S., … Hayes, D. F. (2019). Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 2: Approaches to Predict and Identify Late Recurrence, Research Directions. JNCI Cancer Spectrum, 3(4), pkz049. -
Analysis of Overall Survival Benefit of Abemaciclib Plus Fulvestrant in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer-Reply.
Sledge, G. W., & Frenzel, M. (2020). Analysis of Overall Survival Benefit of Abemaciclib Plus Fulvestrant in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer-Reply. JAMA Oncology. -
MONARCH 2: Interim analysis of overall survival in patients with poor prognostic factors
Neven, P., Johnston, S., Toi, M., Sohn, J., Inoue, K., Pivot, X., … Sledge, G. W. (2020). MONARCH 2: Interim analysis of overall survival in patients with poor prognostic factors. CANCER RESEARCH, 80(4). -
Safety and efficacy of abemaciclib plus endocrine therapy (ET) in elderly patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+, HER2-) advanced breast cancer: An age-specific subgroup analysis of MONARCH 2 and 3 trials
Goetz, M. P., Okera, M., Wildiers, H., Campone, M., Grischke, E.-M., Manso, L., … Sledge, G. W. (2020). Safety and efficacy of abemaciclib plus endocrine therapy (ET) in elderly patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+, HER2-) advanced breast cancer: An age-specific subgroup analysis of MONARCH 2 and 3 trials. CANCER RESEARCH, 80(4). -
Impact of insurance and socioeconomic status on clinical outcomes in therapeutic clinical trials for breast cancer
Obeng-Gyasi, S., O'Neil, A., Zhao, F., Kircher, S. M., Lava, T. R., Wagner, L. I., … Carlos, R. C. (2020). Impact of insurance and socioeconomic status on clinical outcomes in therapeutic clinical trials for breast cancer. CANCER RESEARCH, 80(4). -
The Project Baseline Health Study: a step towards a broader mission to map human health
Arges, K., Assimes, T., Bajaj, V., Balu, S., Bashir, M. R., Beskow, L., … Wong, C. A. (2020). The Project Baseline Health Study: a step towards a broader mission to map human health. NPJ DIGITAL MEDICINE, 3(1), 84. -
Abemaciclib for pre/perimenopausal women with HR+, HER2-advanced breast cancer
Neven, P., Rugo, H. S., Tolaney, S. M., Iwata, H., Toi, M., Goetz, M. P., … Sledge, G. W. (2018). Abemaciclib for pre/perimenopausal women with HR+, HER2-advanced breast cancer. JOURNAL OF CLINICAL ONCOLOGY, 36(15). -
Health-related quality of life (HRQoL) in MONARCH 2: Abemaciclib plus fulvestrant in women with HR+, HER2-advanced breast cancer (ABC) who progressed on endocrine therapy
Kaufman, P. A., Toi, M., Neven, P., Sohn, J., Price, G. L., Lin, Y., … Sledge, G. W. (2018). Health-related quality of life (HRQoL) in MONARCH 2: Abemaciclib plus fulvestrant in women with HR+, HER2-advanced breast cancer (ABC) who progressed on endocrine therapy. JOURNAL OF CLINICAL ONCOLOGY, 36(15). -
Symptom burden and employment status in breast cancer (BC) survivors.
Luis, I. M. V. D., O'Neill, A. M., Sepucha, K., Miller, K. D., Dang, C. T., Northfelt, D. W., … Partridge, A. (2018). Symptom burden and employment status in breast cancer (BC) survivors. JOURNAL OF CLINICAL ONCOLOGY, 36(15). -
Impact of abemaciclib on the time to subsequent chemotherapy and the time to second disease progression across the MONARCH 2 and 3 studies
Tolaney, S. M., Di Leo, A., Cussac, A. L., Dickler, M. N., Campone, M., Iwata, H., … Sledge, G. W. (2018). Impact of abemaciclib on the time to subsequent chemotherapy and the time to second disease progression across the MONARCH 2 and 3 studies. JOURNAL OF CLINICAL ONCOLOGY, 36(15). -
The association of early toxicity and outcomes for patients treated with abemaciclib
Rugo, H. S., Sledge, G. W., Johnston, S. R. D., Goetz, M. P., Martin, M., Toi, M., … Tolaney, S. M. (2018). The association of early toxicity and outcomes for patients treated with abemaciclib. JOURNAL OF CLINICAL ONCOLOGY, 36(15). -
Susan G. Komen Big Data for Breast Cancer Initiative: How Patient Advocacy Organizations Can Facilitate Using Big Data to Improve Patient Outcomes.
Jourquin, J., Reffey, S. B., Jernigan, C., Levy, M., Zinser, G., Sabelko, K., … Sledge, G. (2019). Susan G. Komen Big Data for Breast Cancer Initiative: How Patient Advocacy Organizations Can Facilitate Using Big Data to Improve Patient Outcomes. JCO Precision Oncology, 3. -
Race, ethnicity and clinical outcomes in hormone receptor-positive, HER2-negative, node-negative breast cancer in the randomized TAILORx trial.
Albain, K. S., Gray, R. J., Makower, D. F., Faghih, A., Hayes, D. F., Geyer, C. E., … Sparano, J. A. (2020). Race, ethnicity and clinical outcomes in hormone receptor-positive, HER2-negative, node-negative breast cancer in the randomized TAILORx trial. Journal of the National Cancer Institute. -
Linking insurance claims across time to characterize treatment, monitoring, and end-of-life care in metastatic breast cancer.
Caswell-Jin, J. L., Callahan, A., Purington, N., Han, S. S., Itakura, H., Sledge, G. W., … Kurian, A. W. (2020). Linking insurance claims across time to characterize treatment, monitoring, and end-of-life care in metastatic breast cancer. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. -
MONARCH 2: Subgroup analysis of patients receiving abemaciclib plus fulvestrant as first- and second-line therapy for HR+, HER2-advanced breast cancer.
Neven, P., Johnston, S. R. D., Toi, M., Sohn, J., Inoue, K., Pivot, X., … Sledge, G. W. (2020). MONARCH 2: Subgroup analysis of patients receiving abemaciclib plus fulvestrant as first- and second-line therapy for HR+, HER2-advanced breast cancer. JOURNAL OF CLINICAL ONCOLOGY, 38(15). -
Early discontinuation to adjuvant endocrine therapy in the ECOG-ACRIN TAILORx Trial.
Yanez, B., Gray, R. J., Sparano, J. A., Carlos, R., Sadigh, G., Garcia, S. F., … Wagner, L. (2020). Early discontinuation to adjuvant endocrine therapy in the ECOG-ACRIN TAILORx Trial. JOURNAL OF CLINICAL ONCOLOGY, 38(15). -
Novel Aza-podophyllotoxin derivative induces oxidative phosphorylation and cell death via AMPK activation in triple-negative breast cancer.
Tailor, D., Going, C. C., Resendez, A., Kumar, V., Nambiar, D. K., Li, Y., … Malhotra, S. V. (2020). Novel Aza-podophyllotoxin derivative induces oxidative phosphorylation and cell death via AMPK activation in triple-negative breast cancer. British Journal of Cancer.
Practice Locations
Stanford Women's Cancer Center Palo Alto, CA
Palo Alto, CAStanford Women's Cancer Center
900 Blake Wilbur Drive, 1st Floor
Palo Alto , CA 94304
Make An Appointment More Clinic Information » Getting Here »Important Information about Our Organizations and Physician Affiliation
Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are each independent nonprofit organizations that are affiliated with but separate from each other and from Stanford University. The physicians who provide care at facilities operated by Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are faculty, foundation, or community physicians who are not employees, representatives, or agents of Stanford Health Care, Stanford Health Care Tri- Valley, or Stanford Medicine Partners. Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners do not exercise control over the care provided by such faculty, foundation, and community physicians and are not responsible for their actions.
Patient Reviews
(128 reviews)
View More »
Referring Physicians
PHYSICIAN HELPLINE
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Stanford Health Care provides comprehensive services to refer and track patients, as well as the latest information and news for physicians and office staff. For help with all referral needs and questions, visit Referral Information.
You may also submit a web referral or complete a referral form and fax it to 650-320-9443 or email the Referral Center at ReferralCenter@stanfordhealthcare.org.
- Send referrals online
- Place radiology and lab orders
- View referral status
- Access medical records